Best Gastroenterology Companies in Massachusetts, United States
The 30 best Gastroenterology companies in Massachusetts, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Ironwood Pharma.
Ranked: Best Gastroenterology companies in Massachusetts
| # | Company | Disclosed funding | Last round | Employees | Founded | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Ironwood Pharma Developer of therapeutics for gastrointestinal disorders | $206M | 87 mo ago | 220 | 1998 | Thomas Mccourt CEO | WordPressApple iCloud MailMySQL+27 | — | — |
| 2 | Finch Therapeutics Developer of microbiome-based therapies by using human-first discovery platform | $184M | 74 mo ago | 18 | 2004 | Tom Borody Co-Founder | — | 129 patents Microbiome-based therapeutics for gastrointestinal and neurodevelopmental disorders | — |
| 3 | Gelesis Satiety induction through hydrogel capsules | $182M | 83 mo ago | 93 | 2006 | Yishai Zohar Founder & CEO | PleskPHPVimeo+15 | 173 patents Hydrogel-based oral medical devices for obesity, constipation, and microbiome modulation | — |
| 4 | Evelo Biosciences Developer of therapeutics to treat a range of inflammatory diseases, COVID-19, and cancer | $167M | 40 mo ago | 117 | 2015 | Simba Gill CEO | — | 385 patents Microbiome‑based therapeutics using bacterial and extracellular vesicle formulations | — |
| 5 | Seres Therapeutics Developer of microbiome therapeutics to treat a wide range of diseases | $134M | 29 mo ago | 332 | 2010 | David Berry Founder | DrupalApple iCloud MailMicrosoft 365+24 | 274 patents Therapeutic live bacterial formulations for gut microbiome modulation and infection/cancer treatment | — |
| 6 | NinePoint Medical Advanced medical imaging for real-time tissue microstructure visualization and analysis | $98M | 131 mo ago | 25 | 2008 | — | — | — | — |
| 7 | Alcresta Developer of enzyme-based products for gastrointestinal disorders | $96M | 80 mo ago | 52 52 → 106 (+104%) | 2011 | — | — | 41 patents Targeted dietary fatty acid delivery systems for nutritional supplementation | — |
| 8 | Synta Pharmaceuticals Small molecule drugs for cancer and chronic inflammatory conditions | $90M | 187 mo ago | 37 | 2000 | — | — | 1,214 patents HSP90 inhibitor combination therapies targeting ovarian and other cancers | — |
| 9 | Axcella Developer of targeted therapeutics for infectious and metabolic disorders | $87M | 113 mo ago | 11 | 2008 | — | — | — | — |
| 10 | Auron Therapeutics Developer of cancer therapeutics for the treatment of blood cancer | $63M | 21 mo ago | 27 | 2018 | Kate Yen Co-Founder & CEO | WebflowApple iCloud MailZendesk+11 | — | — |
| 11 | Dynogen Pharmaceuticals 5HT3 receptor-targeted drugs for bowel syndromes | $63M | 271 mo ago | — | — | — | — | — | — |
| 12 | Solarea Bio Innovating microbial solutions for human health, focusing on aging well 29Funding top 29%Moat top 39%Tech top 43%News top 44% All 7 signals ▾Fundingtop 29% Moattop 39% Techtop 43% Newstop 44% Talentbottom 49% Globalbottom 36% Marketbottom 29% Funding: Raised $27.3M across 4 rounds · 4 rounds over 9 yrs (0.4/yr) Moat: Editorial + unicorn rating 7/10 · 10 curated direct competitors tracked rank vs industry peers · Fliar Intelligence Index 29/100 | $27M | 12 mo ago | 24 | 2017 | Gerardo Toledo Co-Founder & CEO | SanityNode.jsHeadless UI+9 | — | — |
| 13 | AltrixBio Developer of therapeutic solutions for treating diabetes & gastrointestinal diseases | $13M | 14 mo ago | 5 | 2019 | — | — | 2 patents Mucoadhesive drug delivery systems for targeted mucosal administration of active agents | — |
| 14 | Suono Bio Developer of technology to enable ultra-rapid delivery of therapeutics to the gastrointestinal tract | $13M | 38 mo ago | 13 | 2015 | C Traverso Co-Founder | — | — | — |
| 15 | ColonaryConcepts Online casino offering diverse games, bonuses, and secure access | $13M | 77 mo ago | 1 | 2013 | Herb Stern Founder & CEO | — | 60 patents Gastrointestinal pharma formulations for constipation, PEG assay kits, and electrolyte replacement foods | — |
| 16 | Olympus Endotechnology America Endoscope insertion devices for Gastrointestinal and Cardiovascular procedures | $8M | 233 mo ago | — | 2005 | Steven Tallarida CEO | — | — | — |
| 17 | Anagram Developer of therapeutics for metabolic diseases | $8M | 6 mo ago | 20 | 2017 | Robert Gallotto President and Chief Executive Officer | — | — | — |
| 18 | Blue Therapeutics Developer of small molecule drugs for neurological disorders | $7M | 66 mo ago | 4 | 2014 | Ajay Yekkirala Co-Founder & CSO | — | — | — |
| 19 | Trine Pharmaceuticals Small molecule drugs for gastrointestinal and metabolic diseases | $6M | 255 mo ago | — | 1992 | Mark Skaletsky CEO | — | — | — |
| 20 | LAPIX Developer of immunotherapies for immunological diseases | $3M | 16 mo ago | 9 | 2019 | Anas Fathallah Co-Founder & CEO | WordPressMySQLPHP+16 | — | — |
| 21 | Bilayer Therapeutics Developer of therapeutics for gastrointestinal diseases | $2M | 39 mo ago | 4 | 2020 | Thomas Collet CEO & President | — | — | — |
| 22 | Oasis Pharmaceuticals Developer of therapeutics to treat inflammatory, fibrotic, and metabolic disorders | $2M | 18 mo ago | — | 2013 | Lidija Covic Founder & CSO | — | — | — |
| 23 | EnVision Endoscopy Developer of devices for gastrointestinal endoscopic surgery | $556K | 75 mo ago | 6 | 2018 | Azadeh Khanicheh Co-Founder | — | 48 patents Minimally invasive endoscopic suturing devices and accessories for gastrointestinal surgery | — |
Top 12 Gastroenterology companies in Massachusetts
#1
Series B · Natick, Massachusetts · founded 2017 · 20 employees$8.2Mraised▾
Developer of therapeutics for metabolic diseases. It offers orally-delivered enzymes as therapies for malabsorption syndrome and nutrient metabolism disorders which is s caused by enzyme deficiencies or genetic mutations.
- May 2026Series B$250M
- Aug 2022Grant (prize money)$1.8M
- Jan 2018Grant (prize money)$3M
- Aug 2017Series A$8.2M
#2
Series B · Cambridge, Massachusetts · founded 2017 · 24 employees$27.3Mraised▾
Innovating microbial solutions for human health, focusing on aging well. The company rapidly innovates and delivers breakthrough solutions for unmet medical needs, particularly in aging health. They are committed to advancing health outcomes through microbial science. Their core values include integrity, scientific rigor, diversity and inclusion, tenacity, a sense of purpose, transparency, and innovation. They develop products to address dietary needs related to rheumatoid arthritis, psoriatic arthritis, and cellular aging. The company uses a rigorous process involving discovery, development, preclinical testing, and clinical trials. They aim to provide trustworthy solutions for health conditions, incorporating the highest level of scientific rigor into every aspect of their process. They are dedicated to improving collective health outcomes and providing transparent formulations.
- Nov 2025Series B$9.9M
- Aug 2024Series B$1M
- May 2023Series B$15M
- Sep 2020Series A$11.3M
#3
Series B · Wellesley, Massachusetts · founded 2018 · 27 employees$63.4Mraised▾
Developer of cancer therapeutics for the treatment of blood cancer. The company has developed its proprietary differentiation therapy used for the treatment of hematologic malignancies. It helps in reactivating endogenous cellular programs to elicit tumor cell maturation and reprogram cancer tissue to a normal phenotype. It can be used to treat acute promyelocytic leukemia (APL) by differentiating malignant promyelocytes into non-cancerous cell neutrophils.
- Feb 2025Series B$27M
- Dec 2024Series B$27.3M
- Jul 2022Series A$48M
- Dec 2020Seed$15.4M
#4
Series A · Cambridge, Massachusetts · founded 2019 · 5 employees$12.8Mraised▾
Developer of therapeutic solutions for treating diabetes & gastrointestinal diseases. The company has developed drug candidate LuCI that helps in the treatment of gastrointestinal (GI) tract infections and also modulates nutrient contact with the bowel mucosa. It has developed drugs that help in treating diabetes and also reduces fats and glucose levels of the body.
- Sep 2025Series A$5M
- Apr 2025Series A$1.2M
- Mar 2019Series A$6.6M
#5
Public · Cambridge, Massachusetts · founded 2010 · 332 employees$134.1Mraised▾
Developer of microbiome therapeutics to treat a wide range of diseases. The product pipeline includes SER-109 for C. difficile infection (CDI), SER-155 for antibiotic-resistant infections and GvHD, and SER 287 for ulcerative colitis.
- 2024Post IPO—
- Nov 2017Grant (prize money)$2.5M
- Dec 2014Series D$65M
- Nov 2014Series C$48M
#6
Series A · Boston, Massachusetts · founded 2019 · 9 employees$3.5Mraised▾
Developer of immunotherapies for immunological diseases. It offers a lead candidate LPX-TI641 for multiple sclerosis, Neuromyelitis Optica, Rheumatology, LPX-TIIBD for Inflammatory bowel disease, and also provides gene therapy.
- Jul 2025Series A$2.2M
- Aug 2024Series A$5.5M
- Oct 2022Seed$1.2M
#7
Public · Cambridge, Massachusetts · founded 2015 · 117 employees$166.5Mraised▾
Developer of therapeutics to treat a range of inflammatory diseases, COVID-19, and cancer. The company focuses on discovering and developing a new class of orally delivered medicines to modulate the immune system through SINTAX, the small intestinal axis. The product pipeline inlcudes EDP1815, EDP1867 and EDP2939 for the treatment of inflammatory diseases, and EDP1908 for the treatment of cancer.
- Jul 2023Post IPO$25.5M
- Mar 2018Series C$81.5M
- Jul 2017Series B$50M
- Nov 2015Series A$35M
#8
Funding Raised · Boston, Massachusetts · founded 2013$2Mraised▾
Oasis Pharmaceuticals is a developer of therapeutic agents for inflammatory, fibrotic and metabolic disorders. The products developed are OA-235i to treat NASH (in phase I), OA-3 hydrogel to treat AD/pruritus (in phase I), and OA-235c to treat IPF (in preclinical stage).
- May 2025Grant (prize money)$2M
#9
Public · Somerville, Massachusetts · founded 2004 · 18 employees$184Mraised▾
Finch Therapeutics is a developer of microbiome-based therapies using a human-first discovery platform. It is using proprietary machine learning techniques to build a clinically annotated library of strains that drive clinical phenotypes of interest. It has also developed an AquaShell for targeted delivery of microbial therapeutics. Its products mainly focussed on Inflammatory Bowel Disease (preclinical), and others.
- Sep 2020Series D$90M
- Jul 2019Series C$53.5M
- Mar 2018Series B$36M
- Jan 2017Series A$3.7M
#10
Public · Cambridge, Massachusetts · founded 1998 · 220 employees$206.3Mraised▾
Developer of therapeutics for gastrointestinal disorders. The company's lead product linaclotide is a guanylate cyclase-C (GC-C) agonist, which is indicated for irritable bowel syndrome with constipation and chronic idiopathic constipation. Also, it offers applications for pediatric GI diseases.
- Aug 2019Post IPO$341M
- Nov 2009Series F$15M
- Sep 2009Series F$25M
- Aug 2009Series F$250K
#11
Public · Boston, Massachusetts · founded 2006 · 93 employees$182.5Mraised▾
Gelesis develops technologies for the treatment of obesity and other unmet medical needs. It offers Attiva, a superabsorbent hydrogel composed entirely from food components, is administered in the form of small particles that are designed to swell after ingestion with water, and occupy the gastric and intestinal cavities, inducing a feeling of satiety that lasts beyond its transit time in the stomach.
- Dec 2019Conventional Debt$8.3M
- Dec 2019Grant (prize money)$12.9M
- Dec 2019Series D$63.4M
- Apr 2019Grant (prize money)$10.6M
#12
Acquired · Newton, Massachusetts · founded 2011 · 52 employees$95.9Mraised▾
Developer of enzyme-based products for gastrointestinal disorders. Its platform technology immobilizes enzymes and attaches them to an insoluble carrier, that can be used to support the digestion and absorption of essential nutrients. Its flagship product Relizorb is a digestive enzyme cartridge that has been designed to mimic the function of pancreatic lipase.
- Feb 2020Series D$10M
- Jan 2019Series D$5M
- Sep 2017Series D$10M
- Mar 2016Series C$50.9M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Gastroenterology coverage by sub-theme.
Regulatory-risk over time flat
Funding & growth over time
funding rising · growth rising